J. F. Smyth

Publication List Details

Period

1986 - 2008

Number

67

Co-Authors

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-{alpha} inhibitor, in patients with advanced cancer (2008)

Brown, E. R., Charles, K. A., Hoare, S. A., Rye, R. L., Jodrell, D. I., Aird, R. E., ...

Background: Tumour necrosis factor-α (TNF-α) is an important regulator of the chronic inflammation contributing to tumour progression. Infliximab, an anti-TNF-α monoclonal antibody was...

Phase II study of E7070 in patients with metastatic melanoma (2005)

Smyth, J. F., Aamdal, S., Awada, A., Dittrich, C., Caponigro, F., Schöffski, P., ...

E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m2 of E7070 as a...

Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines (1999)

Wilson, K.E., Bartlett, J.M.S., Miller, E.P., Smyth, J.F., Mullen, P., Miller, W.R., ...

The extracellular matrix glycoprotein tenascin-C (TN) is overexpressed in the stroma of malignant ovarian tumours particularly at the interface between epithelia and stroma leading to suggestions...

Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomised trial (1997)

Smyth, J. F., Bowman, A., Perren, T., Wilkinson, P., Prescott, R. J., Quinn, K. J., ...

Background Early clinical trials have suggested that glutathione (GSH) offers protection from the toxic effects of cisplatin. Patients and methods One hundred fifty-one patients with ovarian cancer...

Pharmacokinetics, metabolism, tissue and tumour distribution of the neuropeptide growth factor antagonist [Arg6, D-Trp7,9, NmePhe8]-substance P (6--11) in nude mice bearing the H69 small-cell lung cancer xenograft (1995)

Cummings, J., MacLellan, A. J., Jones, D. A., Langdon, S. P., Rozengurt, E., Ritchie, A. A., ...

Background [Arg6, D-Trp7-9, NmePhe8)-Substance P (6–11) (codenamed antagonist G) represents the first broad spectrum antagonist of a number of neuropeptides shown to act as growth factors in...

Gemcitabine in patients with advanced malignant melanoma or gastric cancer: Phase II studies of the EORTC Early Clinical Trials Group (1994)

Sessa, C., Aamdal, S., Wolff, I., Eppelbaum, R., Smyth, J. F., Sulkes, A., ...

Background: Gemcitabine is a water-soluble analogue of deoxycytidine which has shown significant antitumour activity in a broal panel of slow-growing murine and human carcinomas. Objective responses...

Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer (1993)

Vermorken, J. B., Gundersen, S., Clavel, M., Smyth, J. F., Dodion, P., Renard, J., ...

Background: The observed activity of cisplatin in breast cancer and its unattractive toxicity profile in palliative treatment warranted further study of platinum analogues in this disease. Patients...

DNA topoisomerase I and II as targets for rational design of new anticancer drugs (1993)

Cummings, J., Smyth, J. F.

Background: Topoisomerase I and II (topo I and II) are enzymes which alter the topological state of DNA through DNA strand cleavage, strand passage and religation. They participate in most aspects of...

Short report: Phase II trials of fosquidone (GR63178A) in carcinoma of the breast, head and neck, ovary and melanoma (1992)

Kaye, S. B., Wanders, J., Clavel, M., Verweij, J., Piccart, M. J., Smyth, J. F., ...

A total of 91 eligible patients with metastatic cancer have been treated in a series of phase II trials of the novel pentacyclic pyrroloquinone, fosquidone. Tumour types were breast (24), ovary (25),...

Original article: Potentiation of cisplatin by alpha-Interferon in advanced non-small cell lung cancer (NSCLC): A phase II study (1990)

Bowman, A., Fergussion, R.J., Allan, S.G., Stewart, M.E., Gregor, A., Combleet, M.A., ...

Studies in experimental human lung cancer models have suggested that interferon may enhance significantly the response to some cytotoxic drugs. We have performed a phase II study of cisplatin (100...

The Impact of Chemotherapy on Small Cell Carcinoma of the Bronchus (1986)

SMYTH, J. F., FOWLIE, S. M., GREGOR, A., CROMPTON, G. K., BUSUTTIL, A., LEONARD, R. C. F., ...

Between 1971 and 1978, 140 cases of small cell anaplastic carcinoma of the bronchus were registered by a group of chest physicians in north Edinburgh. Sixty-five of these patients received specific...

Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines

Wilson, K.E., Bartlett, J.M.S., Miller, E.P., Smyth, J.F., Mullen, P., Miller, W.R., ...

The extracellular matrix glycoprotein tenascin-C (TN) is overexpressed in the stroma of malignant ovarian tumours particularly at the interface between epithelia and stroma leading to suggestions...

Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia.

Smyth, J F, Poplack, D G, Holiman, B J, Leventhal, B G, Yarbro, G

Adenosine deaminase (ADA) activity has been measured in the lymphoblasts of 23 untreated patients with acute lymphoblastic leukemia and related to the presence or absence of immunologic cell surface...

Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin.

Warrington, P S, Allan, S G, Cornbleet, M A, MacPherson, J S, Smyth, J F, Leonard, R C

Thirty three untreated patients being given cisplatin received metoclopramide (7 mg/kg) for antiemesis by either continuous or intermittent infusion in a random order. Each patient received...

Paraneoplastic hypercalcaemia in ovarian carcinoma.

Allan, S G, Lockhart, S P, Leonard, R C, Smyth, J F

Five patients were seen in whom a raised serum calcium concentration was associated with ovarian carcinoma (clear cell in two cases, cystadenocarcinoma in three). None showed evidence of metastases...

Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?

Smyth, J F, Coleman, R E, Nicolson, M, Gallmeier, W M, Leonard, R C, Cornbleet, M A, ...

OBJECTIVE--To determine the contribution of dexamethasone to the efficacy of the 5-hydroxytryptamine antagonist ondansetron in control of cisplatin induced nausea and vomiting. DESIGN--Randomised...

Intensive investigation in management of Hodgkin's disease.

Sutcliffe, S B, Wrigley, P F, Smyth, J F, Webb, J A, Tucker, A K, Beard, M E, ...

Ninety-eight patients with clinically localised Hodgkin's disease underwent laparotomy and splenectomy to determine the extent of microscopic spread. In 68 patients the procedure was carried out for...

Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia.

Smyth, J F, Poplack, D G, Holiman, B J, Leventhal, B G, Yarbro, G

Adenosine deaminase (ADA) activity has been measured in the lymphoblasts of 23 untreated patients with acute lymphoblastic leukemia and related to the presence or absence of immunologic cell surface...

Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin.

Warrington, P S, Allan, S G, Cornbleet, M A, MacPherson, J S, Smyth, J F, Leonard, R C

Thirty three untreated patients being given cisplatin received metoclopramide (7 mg/kg) for antiemesis by either continuous or intermittent infusion in a random order. Each patient received...

Paraneoplastic hypercalcaemia in ovarian carcinoma.

Allan, S G, Lockhart, S P, Leonard, R C, Smyth, J F

Five patients were seen in whom a raised serum calcium concentration was associated with ovarian carcinoma (clear cell in two cases, cystadenocarcinoma in three). None showed evidence of metastases...

Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?

Smyth, J F, Coleman, R E, Nicolson, M, Gallmeier, W M, Leonard, R C, Cornbleet, M A, ...

OBJECTIVE--To determine the contribution of dexamethasone to the efficacy of the 5-hydroxytryptamine antagonist ondansetron in control of cisplatin induced nausea and vomiting. DESIGN--Randomised...

Intensive investigation in management of Hodgkin's disease.

Sutcliffe, S B, Wrigley, P F, Smyth, J F, Webb, J A, Tucker, A K, Beard, M E, ...

Ninety-eight patients with clinically localised Hodgkin's disease underwent laparotomy and splenectomy to determine the extent of microscopic spread. In 68 patients the procedure was carried out for...

Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines

Wilson, K.E., Bartlett, J.M.S., Miller, E.P., Smyth, J.F., Mullen, P., Miller, W.R., ...

The extracellular matrix glycoprotein tenascin-C (TN) is overexpressed in the stroma of malignant ovarian tumours particularly at the interface between epithelia and stroma leading to suggestions...

Action of deoxycoformycin on human T cell colonies in vitro.

Colledge, N R, Krajewski, A S, Smyth, J F, Wyllie, A H

The potent adenosine deaminase inhibitor, deoxycoformycin (dCF), is currently under evaluation in the treatment of lymphoid malignancy. We show that dCF inhibits the growth in soft agar of T cell...

Role of adenosine deaminase in lymphocyte proliferation.

Hovi, T, Smyth, J F, Allison, A C, Williams, S C

Activity of adenosine deaminase (ADA), an enzyme known to be deficient in some patients with severe combined immunodeficiency, increased three-fold within a 24-hour exposure of human peripheral blood...

Human tumour xenografts growing in immunodeficient mice: a useful model for assessing chemotherapeutic agents in bronchial carcinoma.

Fergusson, R J, Carmichael, J, Smyth, J F

Xenografts from eight human bronchial carcinomas have been established in CBA/Lac mice rendered immunodeficient by neonatal thymectomy followed three weeks later by whole body irradiation (7.35 Gy...

Conducting clinical research in the new NHS: the model of cancer. United Kingdom Coordinating Committee on Cancer Research.

Smyth, J. F., Mossman, J., Hall, R., Hepburn, S., Pinkerton, R., Richards, M., ...

The United Kingdom Coordinating Committee on Cancer Research represents the major organizations funding cancer research in the United Kingdom. The deliberations of a working party convened by the...

Prognostic factors for survival in soft tissue sarcoma.

El-Jabbour, J. N., Akhtar, S. S., Kerr, G. R., McLaren, K. M., Smyth, J. F., Rodger, A., ...

Between 1975 and 1984, 125 cases of histologically confirmed soft tissue sarcomata (STS) were registered in the Department of Clinical Oncology in Edinburgh. Of these, 100 were eligible for analysis...

Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.

Langdon, S. P., Hawkes, M. M., Lawrie, S. S., Hawkins, R. A., Tesdale, A. L., Crew, A. J., ...

To assess the role of oestrogen regulation in the growth of ovarian cancer, we examined the effects of an oestrogen, 17 beta-oestradiol, and an anti-oestrogen, tamoxifen, on oestrogen receptor (ER)...

Transforming growth factor-beta mRNA expression and growth control of human ovarian carcinoma cells.

Bartlett, J. M., Rabiasz, G. J., Scott, W. N., Langdon, S. P., Smyth, J. F., Miller, W. R.

The pattern of TGF beta expression and in vitro response to TGF beta has been defined in three ovarian carcinoma cell lines (PEO1, PEO4 and PEO14). Marked differences in both mRNA expression and...

A Medical Research Council phase II trial of alternating chemotherapy and radiotherapy in small-cell lung cancer. The Medical Research Council Lung Cancer Working Party.

Bleehen, N. M., Girling, D. J., Gregor, A., Leonard, R. C., Machin, D., McKenzie, C. G., ...

In a non-randomised study in six centres in the UK, 24 patients with previously untreated small-cell lung cancer of limited extent were treated with a regimen of alternating chemotherapy and...

Growth control by epidermal growth factor and transforming growth factor-alpha in human lung squamous carcinoma cells.

Rabiasz, G. J., Langdon, S. P., Bartlett, J. M., Crew, A. J., Miller, E. P., Scott, W. N., ...

Although EGF receptor expression is generally elevated in human lung squamous carcinoma, the biological significance of this phenomenon and the role of EGF and TGF-alpha in this disease are poorly...

12-O-tetradecanoylphorbol 13-acetate induced differentiation in human lung squamous carcinoma cells.

Rabiasz, G. J., Langdon, S. P., Anderson, L., Ritchie, A. A., Miller, W. R., Smyth, J. F.

Three human lung squamous carcinoma cell lines (NX002, CX140 and CX143) demonstrate features of squamous differentiation including involucrin synthesis and competence to form cornified envelopes....

Small intestinal mucosal toxicity of cis-platinum--comparison of toxicity with platinum analogues and dexamethasone.

Allan, S. G., Smyth, J. F.

Cis-platinum causes profound gastrointestinal symptoms in patients and these may persist for many days after drug administration. Gut mucosal toxicity may be a factor in the pathogenesis of such...

Adenosine deaminase activity in leukaemia.

Smyth, J. F., Harrap, K. R.

Adenosine deaminase (EC 3.5.4.4., ADA) has been measured in the blast cells of 36 patients with acute lymphoblastic, acute myeloid, chronic myeloid and chronic myeloid blast crisis leukaemia....

Can long-term survival be improved in patients with small-cell lung cancer (SCLC) and good performance status? Medical Research Council Lung Cancer Working Party.

Bleehen, N. M., Girling, D. J., Gregor, A., Leonard, R. C., Machin, D., McKenzie, C. G., ...

Results from a long-term follow-up suggest that in patients with limited small-cell lung cancer (SCLC) and normal performance status intensive alternating chemotherapy and radiotherapy improve...

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.

Sternberg, C. N., Ten Bokkel Huinink, W. W., Smyth, J. F., Bruntsch, V., Dirix, L. Y., Pavlidis, N. A., ...

Docetaxel (Taxotere), a new semisynthetic taxoid, is a potentially important chemotherapeutic agent for the treatment of cancer. Forty patients with bidimensionally measurable advanced adenocarcinoma...

Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours.

Gabra, H., Taylor, L., Cohen, B. B., Lessels, A., Eccles, D. M., Leonard, R. C., ...

Allele imbalance on chromosome 11 loci in ovarian cancer is a frequent event, suggesting the presence of tumour-suppressor genes for ovarian carcinogenesis on this chromosome. Ten highly polymorphic...

Metabolism of the broad-spectrum neuropeptide growth factor antagonist: [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P.

Jones, D. A., Cummings, J., Langdon, S. P., Maclellan, A. J., Higgins, T., Rozengurt, E., ...

Broad-spectrum neuropeptide growth factor antagonists, such as [D-Arg1, D-Phe5, D-Trp7,9, Leu11]substance P (antagonist D) and [Arg6, D-Trp7,9, NmePhe8]substance P(6-11) (antagonist G), are currently...

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer.

Bartlett, J. M., Langdon, S. P., Simpson, B. J., Stewart, M., Katsaros, D., Sismondi, P., ...

The expression of mRNA for the epidermal growth factor (EGF) receptor, EGF and transforming growth factor alpha (TGF-alpha) was determined in 76 malignant, six borderline and 15 benign primary...

Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505.

Meikle, I., Cummings, J., Macpherson, J. S., Smyth, J. F.

Anthracenyl-amino acid conjugates represent a novel chemical class of topoisomerase (topo) inhibitor. NU/ICRF 505 is a lead compound that stabilises topo I cleavable complexes and is actively...

Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously.

Jodrell, D. I., Bowman, A., Stewart, M., Dunlop, N., French, R., MacLellan, A., ...

3,5-Dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine (penclomedine, NSC 338720, CRC 88-04) is an alpha-picoline derivative with anti-tumour activity in preclinical models. Penclomedine...

Activity of a new nitrosourea (TCNU) in human lung cancer xenografts.

Fergusson, R. J., Anderson, L. E., Macpherson, J. S., Robins, P., Smyth, J. F.

The activity of a new nitrosourea (TCNU) based on the endogenous amino acid taurine was assessed in three human lung cancer xenografts growing in immunodeficient mice. Moderate activity (specific...

Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study

Cameron, D A, Cornbleet, M C, Mackie, R M, Hunter, J A A, Gore, M, Hancock, B, ...

In 1989, the Scottish melanoma group initiated a randomized trial, comparing observation alone with 6 months' therapy with low dose interferon α (given subcutaneously 3 MU day–1, thrice weekly),...

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer

McPhillips, F, Mullen, P, Monia, B P, Ritchie, A A, Dorr, F A, Smyth, J F, ...

c-Raf is an essential component of the extracellular related kinase (ERK) signal transduction pathway. Immunohistochemical staining indicated that c-Raf was present in 49/53 ovarian adenocarcinomas...

A prognostic model for ovarian cancer

Clark, T G, Stewart, M E, Altman, D G, Gabra, H, Smyth, J F

About 6000 women in the United Kingdom develop ovarian cancer each year and about two-thirds of the women will die from the disease. Establishing the prognosis of a woman with ovarian cancer is an...

Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)

Sewell, J M, Macleod, K G, Ritchie, A, Smyth, J F, Langdon, S P

The modulating effects of the orally active epidermal growth factor receptor-specific tyrosine kinase inhibitor ZD 1839 (‘Iressa’) on cell growth and signalling were evaluated in four ovarian...

The therapeutic response of bronchial carcinoma xenografts: a direct patient-xenograft comparison.

Shorthouse, A. J., Peckham, M. J., Smyth, J. F., Steel, G. G.

The chemotherapeutic response of a series of patients with bronchial carcinoma has been compared with the response of their xenografts established in immune-suppressed CBA/lac mice. Xenograft...